A Single-dose, Open-label, Parallel-group Study to Assess the Pharmacokinetics of BAF312 in Subjects With Renal Impairment Compared to Subjects With Normal Renal Function

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2013
to quantify the effect of different degrees of renal impairment on the pharmacokinetics of BAF312 (and selected metabolites) and to assess safety and tolerability in order to develop dosing recommendations for subjects with renal impairment
Epistemonikos ID: 95b8e3be686ef744ae1cb8992af5ac1349732322
First added on: May 11, 2024